Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 338 followers
Latest posts
Last updated about 5 hours ago
Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 fail
about 5 hours ago
A phase 3 trial of Novo Nordisk’s ziltivekimab has missed its primary...
Chutes & Ladders—Legend CEO departs without successor in place
about 6 hours ago
Legend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without...
From Abu Dhabi to Brazil, every region is vying for the ‘new emerging economy’ of biotech
about 6 hours ago
Whether it's looming tariff threats or the rise of China, you need...
Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch
about 9 hours ago
Apnimed has raised $192 million for its upsized IPO, with the proceeds...
Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
about 20 hours ago
Following a pair of FDA rejections for its melanoma drug, Replimune’s fortunes...
BMS CEO Boerner doesn’t ‘feel any compulsion to make deals’ despite lack of M&A this year
1 day ago
BMS may have been absent from the dealmaking spree of some of...
Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat
1 day ago
Investors awaiting Bristol Myers Squibb’s key Alzheimer’s psychosis readout for Cobenfy and...
GSK pens $110M biological datasets pact with AI biotech Relation
1 day ago
GSK is boosting its AI chops with a new deal worth up...
Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOs
1 day ago
Attovia Therapeutics, Braveheart Bio and Vogenx have set target ranges for their...
Boston Scientific cuts guidance again after unveiling restructuring plan
1 day ago
Boston Scientific is cutting its financial guidance for the second quarter in...
Takeda scraps another phase 2 celiac disease therapy, narrowing pipeline to one
1 day ago
Takeda has dropped another celiac disease therapy from its phase 2 pipeline...
Labcorp posts higher Q2 earnings on strength of diagnostics, lab services; adjusts full-year guidance
1 day ago
Labcorp continues to power along as it posts strong quarterly earnings led...